Add to ORKGmelanoma; BRAF mutations; vemurafenib; ipilimumab; predictive markers; personalised medicin
The molecular classification of melanoma and the advent of new drugs are changing the paradigm of th...
The BRAF inhibitor vemurafenib is an effective drug in patients with BRAF mutant metastatic melanoma...
Melanoma, a malignant tumor of melanocytes, causes the majority (75%) of all skin cancer-related dea...
melanoma; BRAF mutations; vemurafenib; ipilimumab; predictive markers; personalised medicin
The past decade has seen significant advances in the understanding of molecular pathogenesis of cuta...
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the B...
The incidence of cutaneous melanoma is steadily increasing, mainly in populations of European origin...
In this review, we present the findings from the literature on several new molecules that can be tar...
Melanoma has recently emerged as a poster child for targeted therapies and immunotherapies, with gam...
The introduction of a newly developed target therapy for metastatic melanomas poses the challenge to...
Malignant melanoma of the skin originates from mutations in melanocytes and can be lethal if unrecog...
Today, melanoma is considered as a spectrum of melanocytic malignancies that can be characterized by...
BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoi...
BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 ...
BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and ...
The molecular classification of melanoma and the advent of new drugs are changing the paradigm of th...
The BRAF inhibitor vemurafenib is an effective drug in patients with BRAF mutant metastatic melanoma...
Melanoma, a malignant tumor of melanocytes, causes the majority (75%) of all skin cancer-related dea...
melanoma; BRAF mutations; vemurafenib; ipilimumab; predictive markers; personalised medicin
The past decade has seen significant advances in the understanding of molecular pathogenesis of cuta...
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the B...
The incidence of cutaneous melanoma is steadily increasing, mainly in populations of European origin...
In this review, we present the findings from the literature on several new molecules that can be tar...
Melanoma has recently emerged as a poster child for targeted therapies and immunotherapies, with gam...
The introduction of a newly developed target therapy for metastatic melanomas poses the challenge to...
Malignant melanoma of the skin originates from mutations in melanocytes and can be lethal if unrecog...
Today, melanoma is considered as a spectrum of melanocytic malignancies that can be characterized by...
BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoi...
BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 ...
BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and ...
The molecular classification of melanoma and the advent of new drugs are changing the paradigm of th...
The BRAF inhibitor vemurafenib is an effective drug in patients with BRAF mutant metastatic melanoma...
Melanoma, a malignant tumor of melanocytes, causes the majority (75%) of all skin cancer-related dea...